Kronos Bio Overview

  • Founded
  • 2017
Founded
  • Status
  • Public
  • Employees
  • 63
Employees
  • Stock Symbol
  • KRON
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $27.87
  • (As of Friday Closing)

Kronos Bio General Information

Description

Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 1300 South El Camino Real
  • Suite 300
  • San Mateo, CA 94402
  • United States
+1 (650) 000-0000

Kronos Bio Timeline

2018201920202021
Date FoundedFinancing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Kronos Bio Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$27.87 $29.32 $25.50 - $39.60 $1.56B 56M 176K -$2.34

Kronos Bio Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
Revenue 0 0 0
EBITDA (57,347) (16,460) (6,554)
Net Income (60,752) (16,117) (6,721)
Total Assets 262,556 102,686 12,614
Total Debt 204,742 528 771
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kronos Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kronos Bio‘s full profile, request access.

Request a free trial

Kronos Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Kronos Bio‘s full profile, request access.

Request a free trial

Kronos Bio Executive Team (12)

Name Title Board Seat Contact Info
Norbert Bischofberger Ph.D Chief Executive Officer & Board Member
Yasir Al-Wakeel Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Barbara Kosacz JD Chief Operating Officer, Operations & General Counsel, Legal
Christopher Dinsmore Ph.D Chief Scientific Officer
Traci Carrithers Operations Manager & Executive Coordinator
You’re viewing 5 of 12 executive team members. Get the full list »

Kronos Bio Board Members (10)

Name Representing Role Since
Arie Belldegrun MD Vida Ventures (Boston) Chairman & Board Member 000 0000
David Tanen Self Board Member & Secretary, Administration 000 0000
Elena Ridloff Self Board Member 000 0000
Jakob Loven Ph.D Nextech Invest Board Member 000 0000
John Martin Ph.D Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Kronos Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kronos Bio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kronos Bio‘s full profile, request access.

Request a free trial

Kronos Bio Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 (000 000000 16-Jul-2020 000000000 00000 00 Buildings and Property 0000000 0000000000000 00.0
To view Kronos Bio’s complete investments history, request access »